Glutamate decarboxylase antibody levels predict rate of β-cell decline in adult-onset diabetes☆
References (41)
- et al.
ICA in diabetes mellitus with autoimmune polyendocrine deficiencies
Lancet
(1974) - et al.
Antibodies to pancreatic islet-cells in IDDM with coexistent autoimmune disease
Lancet
(1974) - et al.
64,000 Mr autoantibodies as predictors of IDDM
Lancet
(1990) - et al.
Quantification of islet cell antibodies and prediction of insulin dependent diabetes
Lancet
(1990) - et al.
Fluctuating ICA in unaffected relatives of patients with IDDM
Lancet
(1984) - et al.
ICA and endogenous insulin secretion in Sudanese diabetic children
Diabetes Res. Clin. Pract.
(1992) Pathologic anatomy of the pancreas in juvenile diabetes mellitus
Diabetes
(1965)- et al.
Pancreatic islet cell antibodies in diabetes mellitus correlated with the duration and type of diabetes, coexistent autoimmune disease and HLA-type
Diabetes
(1977) - et al.
Insulin antibodies in insulin-dependent diabetics before insulin treatment
Science
(1983) - et al.
Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins
Nature
(1982)
Identification of the 64K autoantigen in IDDM as the GABA-synthesizing enzyme glutamic acid decarboxylase
Nature
Recombinant GAD representing the single isoform expressed in human islets detects IDDM-associated 64K autoantibodies
Diabetes
Risk for developing IDDM and the presence of islet 64K antibodies
Diabetologia
Persistence of antibodies to a 64,000-Mr islet cell protein after onset of type 1 diabetes
Diabetes
Antibodies to GAD discriminate major diabetes type
Diabetes
Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus
Diabetologia
Islet cell and thyrogastric antibodies in 633 consecutive 15–34 year old patients in the Diabetes Incidence Study in Sweden (DISS)
Diabetes
β-Cell function in relation to ICA during the first 3 years after clinical diagnosis of diabetes in Type II diabetics
Diabetes Care
Predicting IDDM: use of humoral immune markers
Diabetes Rev.
Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD-65) shows 64K ab positivity at onset predicts diabetes type
J. Clin. Invest.
Cited by (60)
Prevention of autoimmune disease: The type 1 diabetes paradigm
2019, The Autoimmune DiseasesPrevention of Autoimmune Disease: The Type 1 Diabetes Paradigm
2013, The Autoimmune Diseases: Fifth EditionThe age of onset of diabetes and glutamic acid decarboxylase titer measured long after diagnosis are associated with the clinical stage of slow-onset type 1 diabetes
2013, Diabetes Research and Clinical PracticeCitation Excerpt :In other words, the time from the onset of disease to each clinical stage did not differ greatly among stages I–III. The follow-up periods of previous prospective studies that examined the relationship between GAD-Ab and β-cell function were 2–6 years [13–18] except for a single longer study (12 years) [11] that did not indicate a cut-off point for GAD-Ab or consider the age of onset. The speed of β-cell destruction is slower in patients with stages I and II than in those with stage III.
Multiple factors affect the loss of measurable C-peptide over 6 years in newly diagnosed 15- to 35-year-old diabetic subjects
2007, Journal of Diabetes and its ComplicationsCitation Excerpt :The latter patients were two to four times more likely to lose C-peptide over a 6-year period following diagnosis than autoantibody-negative patients, depending on the number of autoantibodies present at the time of diagnosis. These findings are consistent with several previously published studies demonstrating that autoantibody positivity confers an increased risk for progression to insulin dependence (Landin-Olsson et al., 1990; Törn, Landin-Olsson, Ostman et al., 2000) and loss of C-peptide (Gottsäter et al., 1993; Gottsäter et al., 1995; Sabbah et al., 1999; Törn, Landin-Olsson, Lernmark et al., 2000; Törn, Landin-Olsson, Lernmark et al., 2001; Borg et al., 2002; Scholin et al., 2004). Additional analysis of the autoantibody-positive patients identified a number of risk factors associated with an increased likelihood of losing β cell function.
Prevention of Autoimmune Disease: Type 1 Diabetes as a Paradigm
2006, The Autoimmune Diseases, Fourth Edition
- ☆
Part of this work was presented in abstract form at the 28th Meeting of the Scandinavian Society for the Study of Diabetes (SSSD), Stockholm, 1993.